吐槽

CVS removing decongestant from shelves after FDA panel says it's ineffective_我的网站

一 |     　　威海8月21日电 题：科技破局金融赋能 山东威海做强蓝色产业　　作者 周艺伟　　威海位于山东半岛东端，三面濒临黄海，北与辽东半岛相对，东与朝鲜半岛隔海相望，海岸线长968千米，约占全国的十八分之一。    CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。　　近年来，依托得天独厚的滨海资源，威海深耕海洋经济，以科技创新赋能特色水产养殖、以金融“活水”浇灌蓝色产业升级，把蔚蓝海域变成富民兴产、可持续发展的“金饭碗”。

二 | 　　成活率从10%到80%，海马养殖的突围之路　　在威海银泽生物科技股份有限公司(简称“银泽生物”)的养殖车间里，一只公海马收缩育儿袋，将数百尾蚊子大小的海马幼体喷入水中。　　这些微小生命降生后需要自行觅食。养殖过程中，只有小到肉眼几乎看不见的微型活虫，才能成为它们的第一口“口粮”。　　银泽生物董事长俞兰良介绍，2014年，该公司开始瞄准海马养殖赛道。

三 | 彼时，受过度捕捞、海水污染以及海马天然繁殖率低等因素影响，全球海马产量显著下降。　　“最早买回一批海马种源，繁育没有成功。第二年想再买，种源企业也‘全军覆没’了。

四 | ”俞兰良回忆说，之后该公司引进原产于澳大利亚的膨腹海马种源，又埋头研究了五年，最终攻克了海马大规模养殖技术。　　最关键的一跃，是海马幼体开口饵料的研发。在此之前，人工养殖海马幼体成活率仅10%，有了专属“婴儿餐”之后，海马幼体成活率升至80%。银泽生物工作人员在海马养殖车间检查海马生长情况。周艺伟 摄　　此外，该公司还建立了海马幼体质量快速鉴别技术，成功解决海马幼体开口、海马疾病防控等技术难题，搭建起海马全生命周期繁育养殖技术体系，海马大规模养殖技术处于世界先进水平。　　凭借坚守与技术突破，银泽生物逐步站稳行业脚跟，成为中国人工养殖海马产业化、规模化最大的公司之一，其人工养殖的海马在中国市场销量排名前三。　　从竭泽而渔到生态养护，守住海洋“金饭碗”　　如果说银泽生物的故事是“从无到有”，那同样位于威海的寻山集团有限公司(简称“寻山集团”)的发展历程则是“从抢到养”。　　寻山集团地处胶东半岛最东端的威海荣成，是以海洋种业、生态养殖、海洋食品、精深提取、休闲渔业为主导产业的农业产业化国家重点龙头企业，坐拥桑沟湾、爱伦湾两大天然海湾。

五 | 　　20世纪60年代以前，当地渔业资源丰富，渔民却面临“守着金饭碗要饭吃”的困境，大量鲜鱼滞销腐烂，只能当作农田肥料。到了20世纪80年代，当地渔船数量渐多、过度捕捞泛滥，天然鱼虾资源几近枯竭。寻山集团海洋牧场运营经理卞大鹏(右一)在介绍养殖的海胆。周艺伟 摄　　寻山集团海洋牧场运营经理卞大鹏表示，1988年，该公司决定从“重捕捞、轻养殖”转向“科技兴海、以养兴渔”。“传统的粗放养殖是什么挣钱养什么、能养多少养多少，单品种高密度养殖很容易把一片海养废。

六 | ”　　针对粗放养殖弊端，寻山集团摸索出了一套“多营养层次生态立体养殖模式”——海面上养海带、龙须菜，中层水域养鲍鱼、扇贝、牡蛎，底层水域养殖海参、真海鞘。各类海洋生物分层栖息，藻类植物净化水体、释放氧气，贝类滤食浮游生物，形成互补共生的自净循环系统。　　目前，寻山集团在桑沟湾及爱伦湾海域养殖基地面积达6.8万多亩，年产鲜海带35万吨；吸纳400多家养殖户到公司海区度夏养殖鲍鱼，鲍鱼年产量达1.5万吨；每年养殖生产牡蛎、扇贝、海参、真海鞘等3万多吨，成为中国重要的藻类、贝类养殖销售集散地和海上粮仓基地。　　金融“活水”精准滴灌海洋经济　　威海水产养殖企业的转型突围与成长壮大，离不开金融力量的长效陪伴。

七 | 　　“农行与寻山集团的合作已超20年。”农行荣成市支行公司业务部副经理刘颂说，此前荣成海带产业遭遇海水温度异常冲击，行业经营承压，农行坚持不抽贷、不断贷，助力企业渡过难关。　　刘颂称，针对海域使用权难以抵押融资的行业痛点，农行率先在荣成试行海域使用权抵押贷款模式，盘活海洋无形资产。2026年一季度，农行荣成市支行投放6800万元(人民币，下同)蓝色金融专项贷款，助力寻山集团采购鲍鱼苗、海带苗与良种繁育技术升级。　　农行威海泽库支行行长刘栋介绍，针对银泽生物这类重研发、负债偏高的水产养殖企业，农行量身打造金融服务“组合拳”：通过农担公司发放300万元“金穗农担贷”纯信用贷款，又以“一项目一方案”追加两笔100万元惠农e贷纯信用经营贷款，免抵押、不增负，精准适配企业经营需求。

八 | 　　随着山东省加快建设海洋强省，农行山东省分行制定《金融支持山东海洋经济高质量发展服务方案》，围绕服务海洋强省建设，探索创新养殖证抵押、海洋知识产权质押、海洋项目收益贷、资产盘活贷等产品，积极发行蓝色公司债、蓝色中期票据，大力支持龙头骨干企业、专精特新企业、中小微涉海主体等重点客户发展，打通金融服务海洋经济的“最后一公里”。　　目前，农行山东省分行金融服务海洋经济相关客户470余家。截至2026年6月末，该行海洋经济相关信贷余额972亿元，较年初增加89亿元。　　“水下看不见的东西，才是关键。”站在爱伦湾的码头上，卞大鹏指着一排排浮筏说，同样看不见的，是金融“活水”如何渗进这片海，不是冷冰冰的放贷收息，而是一场与企业、与生态共同成长的漫长陪伴。

Current article:http://www.bainangmieruopanglaomen.sbs/6pg7/20260826/83781.pptx

Published on:03:44:46